Suscríbete a nuestra revista y podrás leer el contenido exclusivo online
Regístrate y accede a la revistaI notice you’re asking about — likely referring to the clinical decision support resource UpToDate (from Wolters Kluwer), version 21.6.
| Problem | Solution | |---------|----------| | COVID-19 recommendations seem outdated | Cross-check with live guidance | | Missing new drugs (e.g., tezepelumab) | Use Micromedex or PubMed for initial dosing | | Mobile sync fails | Update to latest app version (older server may require IT ticket) | Conclusion UpToDate 21.6 was a robust, clinically sound version that served many hospitals well through the pandemic transition. For today’s practice, if you are still on 21.6, you will miss key updates in cardiology, oncology, and infectious disease. Most institutions now run version 24.x or higher. uptodate 21.6
However, I cannot directly access or reproduce content from UpToDate because it is a copyrighted, subscription-based medical resource. Instead, I can provide you with a of what UpToDate 21.6 represented, its key features at release, how it compares to earlier/later versions, and practical guidance for clinicians using it. I notice you’re asking about — likely referring
Below is an original, informative article written for general medical professional use. What Was New, Why It Mattered, and How to Use It Effectively Published: Practical Clinical Informatics (original content) Target audience: Physicians, NPs, PAs, residents, medical librarians Introduction UpToDate version 21.6 was released as part of the 2021–2022 content cycle (typically version numbers increase every 3 months). While the core functionality remains consistent across versions, each incremental release brings topic updates, new drug interaction data, guideline integrations, and search algorithm improvements. Most institutions now run version 24
Revisa nuestro contenido en todas las plataformas desde un teléfono hasta nuestra revista en papel.
Mantengamos la conversación, búscanos en twitter como @grupoEducar
Tweets by grupoEducarIngresa a nuestra comunidad en Facebook y profundicemos el debate.